Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases

@article{Matsuzaki2005BacteriophageTA,
  title={Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases},
  author={Shigenobu Matsuzaki and Mohammad Rashel and Jumpei Uchiyama and Shingo Sakurai and Takako Ujihara and Masayuki Kuroda and Masahiko Ikeuchi and Toshikazu Tani and Mikiya Fujieda and Hiroshi Wakiguchi and Shosuke Imai},
  journal={Journal of Infection and Chemotherapy},
  year={2005},
  volume={11},
  pages={211-219}
}
Bacteriophage (phage) therapy involves using phages or their products as bioagents for the treatment or prophylaxis of bacterial infectious diseases. Much evidence in support of the effectiveness of phage therapy against bacterial infectious diseases has accumulated since 1980 from animal model studies conducted in Western countries. Reports indicate that appropriate administration of living phages can be used to treat lethal infectious diseases caused by gram-negative bacteria, such as… 
Exploring phage diversity and potential: Development of phage therapy for bacterial infection
TLDR
The overall objectives of this research including isolation and purification of potentially new phages from environments, characterization of the isolated phages based on morphological study, physicochemical attributes, genomic and proteomic analysis, and development into phage therapy against bacterial infection are presented.
AN OVERVIEW OF BACTERIOPHAGE THERAPY OVER ANTIBIOTICS; AS AN ALTERNATIVE FOR CONTROLLING BACTERIAL INFECTIONS
TLDR
The current status of phage therapy against food-borne, animal and human pathogens is presented and special focus is set on phages E. amylovora and Listeria monocytogenes.
Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.
TLDR
This review presents novel strategies for phage-related therapies and describes the current knowledge of natural bacteriophages within the human microbiome to provide an overview of the high number of different methodological concepts.
Lysin Therapy for Staphylococcus aureus and Other Bacterial Pathogens.
  • V. Fischetti
  • Biology, Medicine
    Current topics in microbiology and immunology
  • 2017
TLDR
Lysins can eliminate bacteria both systemically and topically, from mucosal surfaces and biofilms, as evidenced by experimental models of sepsis, pneumonia, meningitis, endocarditis, and mucosal decolonization and may be a much-needed anti-infective in an age of mounting antibiotic resistance.
Bacteriophage as a Therapeutic Agent to Combat Bacterial Infection: A Journey from History to Application
TLDR
This chapter is introduced to brief the concept of phage, phage history, and phage biology with highlights ofphage therapy, phages engineering, as well as phage applications including the future of phages.
Bacteriophages and Phage-Derived Proteins – Application Approaches
TLDR
In this review, several issues of phage and phage-derived protein application approaches in therapy, diagnostics and biotechnology in general are discussed.
Bacteriophages, phage endolysins and antimicrobial peptides - the possibilities for their common use to combat infections and in the design of new drugs.
TLDR
The literature data suggest that bacteriophages, phage endolysins and antimicrobial peptides can be used in combined therapy, thus negating many of the limitations resulting from their specificity as a single antimicrobial agent.
Using phage as a highly specific antibiotic alternative against Methicillin Resistance Staphylococcus aureus (MRSA)
TLDR
Phage can lyse MDR resistant bacteria without being affected by hydrolytic enzymes or ribosomal variations that's mean unlike drug resistance mechanism which bacteria can destroy the drug before can inter the bacteria cell, the phage not effected with such enzyme.
Phage Lysins: Novel Alternative to Antibiotics
  • V. Fischetti
  • Biology, Medicine
    Phage Therapy: A Practical Approach
  • 2019
TLDR
The characteristics and remarkable potency of these enzymes in killing bacteria both in vitro and in vivo are outlined, suggesting that Lysins may be a much-needed anti-infective in an age of mounting antibiotic resistance.
Phage Therapy in the Treatment of Infectious Diseases: An Overview
TLDR
Evaluating phage therapy studies against infections caused by bacterial infections found bacteriophages can provide a new perspective in the development of new drugs to reduce the rate of bacterial infections.
...
...

References

SHOWING 1-10 OF 130 REFERENCES
Therapy of Experimental Pseudomonas Infections with a Nonreplicating Genetically Modified Phage
TLDR
This study suggests that the increased survival rate of Pf3R-treated mice could result from reduced endotoxin release, and the use of a nonreplicating modified phage for the delivery of genes encoding proteins toxic to bacterial pathogens may open up a new avenue in antimicrobial therapy.
Long-circulating bacteriophage as antibacterial agents.
  • C. Merril, B. Biswas, S. Adhya
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 1996
TLDR
A serial-passage technique in mice is developed to select for phage mutants able to remain in the circulatory system for longer periods of time and it is demonstrated that the long-circulating lambda mutants also have greater capability as antibacterial agents than the corresponding parental strain in animals infected with lethal doses of bacteria.
Removal of Group B Streptococci Colonizing the Vagina and Oropharynx of Mice with a Bacteriophage Lytic Enzyme
TLDR
A bacteriophage (phage) lytic enzyme to remove colonizing GBS and may be used to reduce vaginal GBS colonization in pregnant women before delivery or to decontaminate newborns, thus reducing the incidence of GBS-associated neonatal meningitis and sepsis.
The efficacy of Klebsiella pneumoniae bacteriophage in the therapy of experimental Klebsiella infection
TLDR
It was revealed that bacteriophage could be detected in the blood and internal organs of the animals within 24 hours irrespective of the route of its administration: intraperitoneal, intravenous or intranasal, and may become one of alternative antimicrobial remedies, selectively affecting infective agents.
[The efficacy of Klebsiella pneumoniae bacteriophage in the therapy of experimental Klebsiella infection].
TLDR
It was revealed that bacteriophage could be detected in the blood and internal organs of the animals within 24 hours irrespective of the route of its administration: intraperitoneal, intravenous or intranasal, and may become one of alternative antimicrobial remedies, selectively affecting infective agents.
Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model.
TLDR
The findings suggest strongly that phage lysins protect animals from bacteraemia and death, and the simultaneous attack of the pneumococcal peptidoglycan by a lysozyme and an amidase leads to a remarkable effect through enhanced destruction of the bacterial cell wall.
Treatment of experimental infections of mice with bacteriophages.
  • J. Soothill
  • Biology, Medicine
    Journal of medical microbiology
  • 1992
TLDR
Experimental infections of mice support the view that bacteriophages could be useful in the treatment of human infections caused by antibiotic-resistant strains of bacteria.
Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage φMR11
TLDR
The results uphold theacy of phage therapy against pernicious S. aureus infections in humans and suggest that f MR11 may be a potential prototype for gene-modified, advanced therapeutic S.Aureus phages.
Bacteriophage Therapy Rescues Mice Bacteremic from a Clinical Isolate of Vancomycin-Resistant Enterococcus faecium
TLDR
The ability of this phage to rescue bacteremic mice was demonstrated to be due to the functional capabilities of the phage and not to a nonspecific immune effect.
...
...